Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy

The Narodowy Instytut Onkologii Im. Marii Sklodowskiej‑Curie‑Panstwowy Instytut Badawczy in Warsaw is conducting a series of trials focused on Hepatocellular Carcinoma, exploring new combination therapy approaches to improve response rates and survival outcomes.

• Evaluate efficacy of anti‑PD‑1 based combinations
• Assess safety of dual checkpoint blockade
• Compare progression‑free survival across regimens
• Investigate biomarkers predicting treatment benefit
• Explore first‑line therapeutic options for advanced disease

Across 11 trials, 55 investigators are collaborating to bring innovative liver cancer therapies to patients in Europe.

Research at the institute includes targeted investigations of Microsatellite Instability‑High and KRAS mutant metastatic colorectal cancer, testing novel agents and personalized treatment strategies.

• Identify optimal dosing of targeted agents
• Test efficacy of checkpoint inhibitors in MSI‑H disease
• Determine safety of multi‑arm regimens
• Analyze response rates in KRAS‑mutant tumors
• Validate predictive biomarkers for therapy selection

The program emphasizes personalized medicine and collaborates with leading European oncology networks.

The site is advancing immune checkpoint inhibitor research by evaluating combinations such as relatlimab with nivolumab and triple‑agent regimens that include atezolizumab, bevacizumab, and tiragolumab.

• Compare monotherapy versus combination response
• Measure overall survival benefit of added agents
• Assess tolerability of triple‑agent protocols
• Explore synergy between anti‑PD‑L1 and anti‑CTLA‑4 antibodies
• Monitor immune‑related adverse events across cohorts

These efforts reflect a commitment to expanding immunotherapy options for patients across Europe.

A broad solid tumor program investigates KRAS mutation driven cancers and other biomarker‑defined subsets, integrating genomic profiling to guide early‑phase studies such as the MK‑1084 trial.

• Investigate novel agents in KRAS‑mutant cancers
• Evaluate response in lung cancer cohorts
• Determine biomarker prevalence across tumor types
• Conduct early‑phase safety assessments of emerging drugs
• Integrate genomic data into trial design for precision therapy

As Poland’s national oncology institute, the center supports a multidisciplinary team of 55 investigators dedicated to cutting‑edge cancer research.